Ongoing Clinical Trials in BRAF-Mutant CRC
Cathy Eng, MD, FACP, professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses ongoing clinical trials in the <em>BRAF</em>-mutant colorectal cancer patient population.
Cathy Eng, MD, FACP, professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses ongoing clinical trials in theBRAF-mutant colorectal cancer patient population.
The most recent study presented for theBRAF-mutant population was SWOG S1406, which looked at a control arm of irinotecan and cetuximab with or without vemurafenib inBRAF-mutant metastatic colorectal cancer. The study was positive for progression-free survival, which was the primary endpoint.
Eng believes this was an eye-opening study in that it suggests testing patients for the presence of aBRAFmutation and providing patients with a BRAF inhibitor.
